GlycoMimetics Inc expected to post a loss of 5 cents a share - Earnings Preview
05/05/2025 14:26
GlycoMimetics Inc GLYC.OQ GLYC.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for GlycoMimetics Inc is for a loss of 5 cents per share. The one available analyst rating on the shares is "buy". The average consensus recommendation for the biotechnology & medical research peer group is also "Buy". Wall Street's median 12-month price target for GlycoMimetics Inc is $1.00, above its last closing price of $0.26. This summary was machine generated May 5 at 13:26 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Crescent Biopharma
See all newsBrief: Crescent Biopharma - Potential To Initiate First CR-001 Phase 3 Study In Early 2028
Brief: Crescent Biopharma Announces FDA Clearance Of Ind Application For CR-002, A Pd-L1-Targeted Topoisomerase Inhibitor Adc, For The Treatment Of Solid Tumors
Crescent Biopharma posts smaller-than-expected Q2 net loss
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Crescent Biopharma slips on $125 mln share offering